- Home
- GORO vs PHAT Comparison
GORO vs PHAT Comparison
Compare GORO & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GORO | PHAT |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.8M | 590.6M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GORO | PHAT |
|---|---|---|
| Price | $3.38 | $6.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $20.09 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $1,049.78 | $80.58 |
| Revenue Next Year | $103.57 | $56.62 |
| P/E Ratio | $70.67 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $0.62 | $6.52 |
| 52 Week High | $4.24 | $18.31 |
Technical Indicators
Market Signals| Indicator | GORO | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 42.19 |
| Support Level | $3.37 | $6.91 |
| Resistance Level | $4.00 | $9.74 |
| Average True Range (ATR) | 0.17 | 0.37 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 62.77 | 47.08 |
Price Performance
Historical ComparisonAbout GORO Gold Resource Corporation
Goldgroup Mining Inc is focused on the acquisition, exploration and development of stage gold-bearing mineral properties in the Americas. The Companies current gold production and exploration and development related activities are conducted in Mexico. It property portfolio include Cerro Prieto project in Sonora and Pinos Project.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.